Anthony E. Maida is a businessperson who founded BioConsul Drug Development Corp. and who has been the head of 7 different companies.
He occupies the position of Chairman at Dendri Therapeutics, Inc. and Director & Chief Clinical Officer at Oncotelic Therapeutics, Inc.
He is also on the board of Oncotelic, Inc. and Member of American Chemical Society, Member of American Society of Clinical Oncology, Member of American Association for Cancer Research, Member of The Society of Neuro-Oncology, Member of International Society for Biological Therapy of Cancer, Member of The American Association of Immunologists, Member of Society of Toxicology and Member of Society For Immunotherapy of Cancer.
He previously occupied the position of Chairman of BioConsul Drug Development Corp., Chief Executive Officer for Trellis Bioscience, Inc., President & Chief Executive Officer of Replicon NeuroTherapeutics, Inc., Chief Financial Officer & Vice President for Lockheed Dataplan, Inc., Senior Vice President-Clinical Research at Northwest Biotherapeutics, Inc., Principal at Anthony Maida Consulting International, President & Chief Executive Officer for Jenner Biotherapies, Inc., President & Chief Executive Officer of CancerVax Corp., President & Chief Executive Officer at Cell Pathways, Inc., Chief Financial Officer & Vice President for Data Plan, Inc., VP-Clinical Research & GM-Oncology Worldwide at PharmaNet, Inc. and Senior Financial Controller at Lockheed Missiles & Space Co.
He received an undergraduate degree and a graduate degree from San Jose State University, an MBA and an undergraduate degree from Santa Clara University and a doctorate from the University of California.